Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1711-1715

  Xie, Lin ^a   Shen, Li Da ^a   Qing, Chen ^a   Yang, Zuo Zhang ^a   Li, Ke ^a   Li, Yang ^a   Yang, Ji Lan ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Anti angiogenesis therapy; MVD; Primary malignant gastric lymphoma; Prognosis; VEGF

Indexed keywords

VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STOMACH LYMPHOMA;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84872790030     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0008-8     Document Type: Article

References (27)

1. Ferrarar N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
2. Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL. A peptidomimetic antagonist of the integrin alpha (v) beta 3 inhibits leydig cell tumor growth and development of hypercalcemia of malignancy. Cancer Res. 1998;58:1930-5.
3. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153-5.
4. Weidner N, Semple JP, Welch W, Folkman J. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
5. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart M. Quantitative angiogenesis assessed by anti-PECAM antibodies: correlation with node metastasis and survival in breast cancer. Lancet. 1992;340:1120-4.
6. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994;144:1188-94.
7. Wakui S, Furusato M, Sasaki H, Akiyama A, Kinoshito I, Asano K. Tumor angiogenesis in prostatic carcinoma with and without bone metastasis: a morphometric study. J Pathol. 1992;168: 257-62.
8. Macchiarini P, FontaniniGHardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small cell lung carcinoma. Lancet. 1992;340:145-6.
9. Bigler SA, Deering RE, Brawer MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24:220-6.
10. Smith-McCune KS, Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994;54:804-8.
11. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252-60.
12. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin's lymphoma. Cancer. 1980;46:215-22.
13. Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol. 2007;136:521-38.
14. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101: 1159-70.
15. Buchler P, Reber HA, Buchler MW, Friess H, Hines OJ. VEGF influences the prognosis of panc reatic cancer. Ann Surg. 2002; 236:728-49.
16. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
17. Ding G, Huang S, Chen XJ, Liu DH. The Relationship between VEGF in Experimental Rat and Tumor Angiogenesis Invasion and Metastasis. Pract J Cancer. 2010;25:551-3.
18. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-10.
19. Yu MJ, Li HM. Advances in angiogenesis inhibitors of lymphoma. Journal of Pract Oncol. 2005;19:69-72.
20. Tang QL, Jiang XF, Yang KZ, Li HG, Liu WP, Peng ZL. Expression of VEGF and its significance in primary diffuse large B-cell lymphoma of the female genital system. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009;40:48-51.
21. Ni Q, Wu ZS, Wu Q, Zhang SM, Zhou Q, Wang Y. Expression of ESM-1 and VEGF in non-Hodgkin lymphoma. Anhui Med Pharm J. 2004;9:104-5.
22. Filipits M, Jaeger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res. 2000;6: 3417-23.
23. Zeng CQ, Zheng Y, Huang LX, Li JD. Analysis of prognostic factors in lymph node-negative advanced gastric cancer patients. Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:111-3.
24. Verheul HM, Hoekmank K, Joma AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5:45-50.
25. Ho CL, Sheu LF, Li CY. Immunohistochemical Expression of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor, and Their Receptors in Stage IV Non-Hodgkin Lymphoma. Appl Immunohistochem Mol Morphol. 2002;10:316-21.
26. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998-1005.
27. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697-707.